DDInter742 DDInter1676
An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Floxuridine {u} (Compound) resembles {v} (Compound) Trifluridine
Floxuridine {u} (Compound) resembles {v} (Compound) Emtricitabine
Floxuridine {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Floxuridine {u} (Compound) treats {v} (Disease) stomach cancer
Floxuridine {u} (Compound) binds {v} (Gene) TYMS
Floxuridine {u} (Compound) upregulates {v} (Gene) PMAIP1
Floxuridine {u} (Compound) is included by {v} (Pharmacologic Class) Deoxyuridine
Floxuridine {u} (Compound) downregulates {v} (Gene) PPP2R3C
Floxuridine {u} (Compound) causes {v} (Side Effect) Myocardial ischaemia
Floxuridine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gemifloxacin
Floxuridine (Compound) resembles Trifluridine (Compound)
Floxuridine (Compound) resembles Emtricitabine (Compound)
Floxuridine may lead to a major life threatening interaction when taken with Cladribine
Floxuridine (Compound) treats stomach cancer (Disease)
Floxuridine (Compound) binds TYMS (Gene)
Floxuridine (Compound) upregulates PMAIP1 (Gene)
Floxuridine (Compound) is included by Deoxyuridine (Pharmacologic Class)
Floxuridine (Compound) downregulates PPP2R3C (Gene)
Floxuridine (Compound) causes Myocardial ischaemia (Side Effect)
Floxuridine may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin